$TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Healthcare
Sector
Biotechnology
Industry
Bobak R. Azamian
CEO
323
Employees
$64.51
Current Price
$2.58B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 8 | 24 | $7,096,950.79 | 103,771 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 8 | 24 | $7,096,950.79 | 103,771 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 8 | 25 | $7,738,372.01 | 112,137 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 8 | 25 | $7,738,372.01 | 112,137 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 8 | 31 | $9,489,145.38 | 133,702 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.19
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history